Novo Nordisk’s Alzheimer’s Trials Show No Significant Progress

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk advances amycretin to late-stage trial after positive diabetes weight-loss results

Novo Nordisk’s experimental drug amycretin shows strong results in its mid-stage trial, helping type 2 diabetes patients lose up to 14.5% of their body weight.

Novo’s next-gen obesity drug shows positive results, heads to late-stage testing

Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to ...

What's Happening With Novo Nordisk Stock?

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.

Novo Nordisk (NVO) is Trending On Reddit – Here’s Why

We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Novo Nordisk A/S (NYSE:NVO) ...

Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.

Novo Nordisk stock was rebounding Tuesday. It’s a tale of two drug trials.The Danish pharmaceutical giant said its new ...

Why Novo Nordisk Stock Sank 5.6% Today

Shares of Novo Nordisk (NYSE: NVO) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq ...

Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk

Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers ...